Long chain non-encoding RNA sequence for early diagnosis of human prostatic cancer and its application

A long-chain non-coding, prostate cancer technology, applied in the field of cancer joint diagnostic markers, long-chain non-coding RNA expression inhibitors, can solve the problem of limiting the clinical application value of PCA3, and has not found that it can effectively or accurately detect the early occurrence of prostate cancer and other problems, to achieve the effect of accurate cDNA sequence results, high accuracy and high sensitivity
CN107699564AActive Publication Date: 2018-02-16SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI
4 Cites 8 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI
Publication Date
2018-02-16

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a full-length cDNA sequence of long chain non-encoding RNA for early diagnosis of human prostatic cancer and its application. An accurate sequence of the PRCAT38 is cloned for the first time, and a foundation for further studying the function of the PRCAT 38 in the generation and development processes of the prostatic cancer is laid. The specificity high expression of the PRCAT 38 in the prostatic cancer cells and tissues can influence the proliferation, clone formation and migration of the prostatic cancer cells, and the PRCAT 38 can be applied to prepare the product for the early diagnosis, prognosis evaluation and / or treatment of the prostatic cancer. The invention provides a cancer diagnosis marker, which comprises PRCAT 38, EZH2 and miR-24-2, the marker has highsensitivity and high specificity to detect prostate. The invention provides an expression inhibitor of the long chain non-encoding RNA, which comprises siRNA and / or shRNA; the expression inhibition can inhibit the expression of PRCAT38 and EZH2 at the same time, and is good for the gene treatment and clinical drug research and development of the prostatic cancer.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of tumor molecular biology, and in particular relates to a precise cDNA sequence of a prostate cancer-specific long-chain non-coding RNA, a preparation method of the sequence, a combined cancer diagnostic marker, and an expression inhibitor of a long-chain non-coding RNA and its uses. Background technique

[0002] Prostate cancer (PCa) is a malignant tumor that occurs in the prostate epithelium. It is the most common and unique malignant tumor in the male reproductive system. The incidence of prostate cancer continues to increase with age, and 95% of it occurs in people over 60 years old. elderly male. In the past ten years, about one million prostate cancer patients are newly diagnosed each year, accounting for about 15% of new male cancer cases worldwide, ranking second in the incidence of all male malignant tumors. The incidence of prostate cancer in the United States has surpassed that of prostate cancer, becomi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More